SAFETY, TOLERABILITY AND IMMUNOGENICITY OF 15-VALENT PNEUMOCOCCAL CONJUGATE VACCINE+PPV23 12 MONTHS LATER IN HEALTHY ADULTS = 50

Por: Song, J, Chang, C, Andrews, C, Diez-Domingo, J, Oh, M, Dagan, R, Musey, L, Buchwald, U, Hartzel, J, Pedley, A, Li, J, Sterling, T, Tamms, G, Chiarappa, J, Lutkiewicz, J and Tu, Y

---

Publicada: 14 jun 2022

---

---

Filiaciones:
Song, J:
 Korea Univ, Coll Med, Seoul, South Korea

Chang, C:
 Natl Cheng Kung Univ, Tainan, Taiwan

Andrews, C:
 Diagnost Res Grp, San Antonio, TX USA

:
 FISABIO, Valencia, Spain

Oh, M:
 Seoul Natl Univ, Coll Med, Seoul, South Korea

Dagan, R:
 Ben Gurion Univ Negev, Beer Sheva, Israel

Buchwald, U:
 Merck & Co Inc, Kenilworth, NJ USA

Hartzel, J:
 Merck & Co Inc, Kenilworth, NJ USA

Pedley, A:
 Merck & Co Inc, Kenilworth, NJ USA

Li, J:
 Merck & Co Inc, Kenilworth, NJ USA

Sterling, T:
 Merck & Co Inc, Kenilworth, NJ USA

Tamms, G:
 Merck & Co Inc, Kenilworth, NJ USA

Chiarappa, J:
 Merck & Co Inc, Kenilworth, NJ USA

Lutkiewicz, J:
 Merck & Co Inc, Kenilworth, NJ USA

Tu, Y:
 Merck & Co Inc, Kenilworth, NJ USA